Ensign Peak Advisors Inc Trims Position in STAAR Surgical (NASDAQ:STAA)

Ensign Peak Advisors Inc cut its position in STAAR Surgical (NASDAQ:STAAGet Rating) by 9.1% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 776,098 shares of the medical instruments supplier’s stock after selling 78,140 shares during the period. Ensign Peak Advisors Inc owned about 1.63% of STAAR Surgical worth $70,857,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also recently made changes to their positions in the company. Allegheny Financial Group LTD bought a new stake in STAAR Surgical in the 4th quarter valued at $25,000. Covestor Ltd bought a new stake in STAAR Surgical in the 4th quarter valued at $39,000. Lindbrook Capital LLC bought a new stake in STAAR Surgical in the 4th quarter valued at $59,000. PNC Financial Services Group Inc. increased its holdings in STAAR Surgical by 14.7% in the 3rd quarter. PNC Financial Services Group Inc. now owns 1,237 shares of the medical instruments supplier’s stock valued at $160,000 after acquiring an additional 159 shares during the last quarter. Finally, Macquarie Group Ltd. increased its holdings in STAAR Surgical by 191.8% in the 3rd quarter. Macquarie Group Ltd. now owns 1,395 shares of the medical instruments supplier’s stock valued at $179,000 after acquiring an additional 917 shares during the last quarter. 89.93% of the stock is owned by hedge funds and other institutional investors.

NASDAQ:STAA traded up $0.04 during trading hours on Thursday, hitting $56.74. 13,015 shares of the company were exchanged, compared to its average volume of 706,469. The stock has a market capitalization of $2.71 billion, a price-to-earnings ratio of 97.98 and a beta of 1.18. STAAR Surgical has a 52-week low of $49.03 and a 52-week high of $163.08. The company’s 50 day moving average price is $65.96 and its 200-day moving average price is $80.02.

STAAR Surgical (NASDAQ:STAAGet Rating) last released its quarterly earnings data on Wednesday, May 4th. The medical instruments supplier reported $0.21 EPS for the quarter, beating the consensus estimate of $0.10 by $0.11. STAAR Surgical had a net margin of 11.98% and a return on equity of 12.78%. The business had revenue of $63.20 million for the quarter, compared to the consensus estimate of $60.53 million. During the same period in the prior year, the firm earned $0.13 EPS. The business’s revenue for the quarter was up 24.5% on a year-over-year basis. As a group, equities research analysts predict that STAAR Surgical will post 0.62 EPS for the current year.

In other STAAR Surgical news, VP James E. Francese sold 922 shares of the stock in a transaction dated Monday, March 21st. The shares were sold at an average price of $74.62, for a total transaction of $68,799.64. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 3.60% of the stock is owned by corporate insiders.

A number of analysts have issued reports on the stock. BTIG Research reiterated a “buy” rating and issued a $98.00 price target on shares of STAAR Surgical in a report on Saturday, April 23rd. Needham & Company LLC reissued a “buy” rating and issued a $87.00 price objective on shares of STAAR Surgical in a research note on Tuesday, May 3rd. Canaccord Genuity Group lifted their price objective on shares of STAAR Surgical from $81.00 to $89.00 and gave the stock a “buy” rating in a research note on Tuesday, April 26th. StockNews.com assumed coverage on shares of STAAR Surgical in a research note on Thursday, March 31st. They issued a “hold” rating for the company. Finally, Benchmark raised shares of STAAR Surgical from a “hold” rating to a “buy” rating and set a $97.00 price objective for the company in a research note on Monday, March 28th. Two research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to data from MarketBeat, STAAR Surgical presently has a consensus rating of “Buy” and an average price target of $95.14.

STAAR Surgical Company Profile (Get Rating)

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides Visian implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness.

Recommended Stories

Institutional Ownership by Quarter for STAAR Surgical (NASDAQ:STAA)

Receive News & Ratings for STAAR Surgical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STAAR Surgical and related companies with MarketBeat.com's FREE daily email newsletter.